CIK 0001022899 · Non-accelerated filer<br>Smaller reporting company
Protagenic Therapeutics, Inc.new
Sign in to watch- Ticker
- PTIX
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 061390025
- Phone
- (212) 994-8200
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- Atrinsic, Inc., NEW MOTION, INC., MPLC, Inc., MILLBROOK PRESS INC
- Open-market buys, last 90 days
- $23,756
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$23,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2008-01-29 | Legator Allan CFO and Secretary | Option exercise | +50,000 | $0.48 | $24K | 50,000 |
| 2008-01-29 | Legator Allan CFO and Secretary | Option exercise · Stock Option (Right to Buy) | +50,000 | 240,548 | ||
| 2007-11-30 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +12,500 | $14.00 | $175K | 1,495,000 |
| 2007-09-25 | Klier Gil Director | Grant or award · Option (Right to Buy) | +25,000 | 25,000 | ||
| 2007-03-08 | WALKER SCOTT Chief Marketing Officer | Other disposition · Options (Right to Buy) | −174,328,512 | 0 | ||
| 2007-03-08 | WALKER SCOTT Chief Marketing Officer | Grant or award · Options (Right to Buy) | +11,250,000 | 11,250,000 | ||
| 2007-03-08 | WALKER SCOTT Chief Marketing Officer | Sale · Series C Convertible Preferred Stock | −53,538.86 | 108,039.14 | ||
| 2007-02-17 | Larner Drew Director | Grant or award · Options to Purchase Common Stock | +7,500,000 | 7,500,000 | ||
| 2007-02-16 | CHAZEN JEROME A Director | Grant or award · Options to Purchase Common Stock | +15,000,000 | 15,000,000 | ||
| 2007-02-16 | Regenstein Barry Director | Grant or award · Options to Purchase Common Stock | +7,500,000 | 7,500,000 | ||
| 2007-02-16 | Katz Burton Chief Executive Officer | Grant or award · Options to Purchase Common Stock | +24,375,000 | 24,375,000 | ||
| 2007-02-12 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +360,000,000 | $0.01 | $3.5M | 429,750,000 |
| 2007-02-12 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +360,000,000 | $0.01 | $3.5M | 429,750,000 |
| 2006-10-24 | Banon Sid Former Director | Sale | −586,222 | $0.02 | $12K | 59,503 |
| 2006-10-24 | CHAZEN JEROME A Director | Sale | −2,344,887 | $0.02 | $47K | 238,011 |
| 2006-10-24 | KIER ISAAC Director | Sale | −17,586,652 | $0.02 | $352K | 1,785,085 |
Page 10 of 10 · 196 trades